{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:46:05Z","timestamp":1794361565041,"version":"4.9.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.vaccine.2007.01.111","type":"journal-article","created":{"date-parts":[[2007,2,17]],"date-time":"2007-02-17T12:03:38Z","timestamp":1171713818000},"page":"3752-3762","source":"Crossref","is-referenced-by-count":424,"title":["Vaccine adjuvants revisited"],"prefix":"10.1016","volume":"25","author":[{"given":"J.C.","family":"Aguilar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.G.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2007.01.111_bib1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib2","unstructured":"Vogel FR. Adjuvants in perspective. In: Brown F, Haaheim LR, editors. Modulation of the immune response to vaccine antigens. Dev. Biol. Stand. vol 92. Basel: Karger; 1998. p. 241\u20138."},{"key":"10.1016\/j.vaccine.2007.01.111_bib3","first-page":"227","article-title":"Sur l\u2019augmentation anormale de l\u2019antitoxine chez les chevaux producteurs de serum antidiphterique","volume":"101","author":"Ramon","year":"1925","journal-title":"Bull Soc Centr Med Vet"},{"key":"10.1016\/j.vaccine.2007.01.111_bib4","first-page":"1","article-title":"Procedes pour accro\u00eftre la production des antitoxins","volume":"40","author":"Ramon","year":"1926","journal-title":"Ann Inst Pasteur"},{"key":"10.1016\/j.vaccine.2007.01.111_bib5","first-page":"38","article-title":"The antigenic value of toxoid precipitated by potassium-alum","volume":"29","author":"Glenny","year":"1926","journal-title":"J Path Bact"},{"key":"10.1016\/j.vaccine.2007.01.111_bib6","series-title":"Vaccine design: the subunit and adjuvant approach","first-page":"234","article-title":"A summary compendium of vaccine adjuvants and excipients","author":"Vogel","year":"1995"},{"key":"10.1016\/j.vaccine.2007.01.111_bib7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3181\/00379727-37-9625","article-title":"Sensitization and antibody formation after injection of tubercle bacili and parafin oil","volume":"37","author":"Freund","year":"1937","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2007.01.111_bib8","article-title":"Adjuvant influenza vaccines","volume":"41","author":"Stuart-Harris","year":"1969","journal-title":"Bull WHO"},{"key":"10.1016\/j.vaccine.2007.01.111_bib9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1084\/jem.103.2.225","article-title":"Studies on the O-antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide","volume":"103","author":"Johnson","year":"1956","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2007.01.111_bib10","series-title":"The theory and practical application of adjuvants","first-page":"21","article-title":"Aluminium adjuvants","author":"Lindblad","year":"1995"},{"key":"10.1016\/j.vaccine.2007.01.111_bib11","series-title":"Laboratory Methods in Immunology","first-page":"39","article-title":"Immunologic adjuvants: general properties, advantages, and limitations","author":"Byars","year":"1990"},{"key":"10.1016\/j.vaccine.2007.01.111_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/clinids\/2.3.370","article-title":"Vaccine adjuvants","volume":"2","author":"Edelman","year":"1980","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2007.01.111_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.14.1.275","article-title":"Antigen sampling across epithelial barriers and induction of mucosal immune responses","volume":"14","author":"Neutra","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.iy.04.040186.002101","article-title":"Future prospects for vaccine adjuvants","volume":"4","author":"Warren","year":"1986","journal-title":"CRC Crit Rev Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib15","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1089\/aid.1992.8.1409","article-title":"An update on vaccine adjuvants in clinical trials","volume":"8","author":"Edelman","year":"1992","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2007.01.111_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0161-5890(91)90074-T","article-title":"Immunological adjuvants: desirable properties and side-effects","volume":"28","author":"Allison","year":"1991","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib17","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1128\/IAI.51.3.816-825.1986","article-title":"Uveitis induction in the rabbit by muramyl dipeptides","volume":"51","author":"Waters","year":"1986","journal-title":"Infect Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib18","first-page":"S45","article-title":"Safety evaluation of vaccine adjuvants","volume":"9","author":"Goldenthal","year":"1993","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2007.01.111_bib19","series-title":"Immunological adjuvants and vaccines","first-page":"213","article-title":"Recommendations for the assessment of adjuvants","author":"Stewart-Tull","year":"1989"},{"key":"10.1016\/j.vaccine.2007.01.111_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/08830189009061764","article-title":"Adjuvants","volume":"7","author":"Edelman","year":"1990","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJMp048006","article-title":"Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy","volume":"350","author":"Couch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2007.01.111_bib22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM200102223440804","article-title":"Intussusception among infants given an oral rotavirus vaccine","volume":"344","author":"Murphy","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2007.01.111_bib23","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1128\/JVI.68.3.1418-1425.1994","article-title":"Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implications for the pathogenesis of HBV-induced hepatitis","volume":"68","author":"Schirmbeck","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib24","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/infdis\/174.6.1168","article-title":"MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates","volume":"174","author":"Traquina","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2007.01.111_bib25","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/eji.1830260915","article-title":"In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production","volume":"26","author":"Brewer","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib26","first-page":"161","article-title":"Dur\u00e9e du s\u00e9jour de l\u2019antig\u00e8ne dans l\u2019organisme et immunit\u00e9","volume":"4","author":"Blagowechensky","year":"1938","journal-title":"Rev Immunol Par\u00eds"},{"key":"10.1016\/j.vaccine.2007.01.111_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3181\/00379727-156-39951","article-title":"Eosinophil response to alum adjuvants: involvement of T cells in non-antigen-dependent mechanisms","volume":"156","author":"Walls","year":"1977","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2007.01.111_bib28","series-title":"Vaccine design: the subunit and adjuvant approach","first-page":"229","article-title":"Adjuvant properties of aluminium and calcium compounds","author":"Gupta","year":"1995"},{"key":"10.1016\/j.vaccine.2007.01.111_bib29","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/bmj.1.5645.663","article-title":"Advantages of aluminum hydroxide adsorbed diphtheria, tetanus and pertussis vaccines for the immunization of infants","volume":"1","author":"Butler","year":"1969","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2007.01.111_bib30","first-page":"149","article-title":"Comparison of tissue reactions produced by Haemophilus pleuropneumoniae vaccines made with six different adjuvants in swine","volume":"49","author":"Straw","year":"1985","journal-title":"Can J Comp Med"},{"key":"10.1016\/j.vaccine.2007.01.111_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0167-5699(93)90046-N","article-title":"Adjuvants: current status, clinical perspectives and future prospects","volume":"14","author":"Audibert","year":"1993","journal-title":"Immunol Today"},{"key":"10.1016\/j.vaccine.2007.01.111_bib32","series-title":"Immunological adjuvants and vaccines","first-page":"35","article-title":"Aluminium salts: perspectives in their use as adjuvants","author":"Bomford","year":"1989"},{"key":"10.1016\/j.vaccine.2007.01.111_bib33","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/0264-410X(93)90377-A","article-title":"Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines","volume":"11","author":"Goto","year":"1993","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib34","first-page":"321","article-title":"Etude de la vaccination antidiphterique de sujets alergiques avec une anatoxine pure adsorbee sur phosphate de calcium","volume":"30","author":"Relyveld","year":"1964","journal-title":"Bull WHO"},{"key":"10.1016\/j.vaccine.2007.01.111_bib35","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/0264-410X(95)00011-O","article-title":"Adjuvants for human vaccines-current status, problems and future prospects","volume":"13","author":"Gupta","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib36","first-page":"131","article-title":"Preparation and use of calcium phosphate adsorbed vaccines","volume":"65","author":"Relyveld","year":"1986","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2007.01.111_bib37","first-page":"1","article-title":"Saponins as vaccine adjuvants","volume":"13","author":"Kensil","year":"1996","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.vaccine.2007.01.111_bib38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/344873a0","article-title":"Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs","volume":"344","author":"Takahashi","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2007.01.111_bib39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0165-2427(87)90135-8","article-title":"Adjuvants","volume":"17","author":"Dalsgaard","year":"1987","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib40","series-title":"Immunopharmacology of infectious diseases: vaccine adjuvants and modulators of non-specific resistance","first-page":"65","article-title":"The differential adjuvant activity of Al(OH)3 and saponin","author":"Bomford","year":"1987"},{"key":"10.1016\/j.vaccine.2007.01.111_bib41","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/0264-410X(95)00105-A","article-title":"Adjuvant activity of non toxic Quillaja saponaria Molina components for use in iscom-matrix","volume":"13","author":"R\u00f6nnberg","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib42","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.146.2.431","article-title":"Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex","volume":"146","author":"Kensil","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib43","series-title":"Vaccine design: the subunit and adjuvant approach","first-page":"525","article-title":"Structural and immunological characterization of the vaccine adjuvant QS-21","author":"Kensil","year":"1995"},{"key":"10.1016\/j.vaccine.2007.01.111_bib44","first-page":"302","article-title":"Immunoadjuvant activities of cells walls, their water soluble fractions and peptidoglycan subunits, prepared from various gram-positive bacteria, and of synthetic N-acetylmuramyl peptides","volume":"149S","author":"Kotani","year":"1975","journal-title":"Z Immunitatsforsch"},{"key":"10.1016\/j.vaccine.2007.01.111_bib45","series-title":"Biological response moodifiers. New approaches to disease prevention","first-page":"307","article-title":"Muramyl peptides as immunopharmacological response modifiers","author":"Audibert","year":"1985"},{"key":"10.1016\/j.vaccine.2007.01.111_bib46","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0008-8749(76)90053-8","article-title":"Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components","volume":"21","author":"Audibert","year":"1976","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib47","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/IAI.27.3.826-831.1980","article-title":"Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of a desmuramyl peptidolipid analogue","volume":"27","author":"Parant","year":"1980","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2007.01.111_bib48","first-page":"353","article-title":"Synthetic immunomodulators and synthetic vaccines","volume":"2","author":"Leclerc","year":"1986","journal-title":"CRC Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.vaccine.2007.01.111_bib49","first-page":"625","article-title":"T cell and interferon-gamma involvement in the adjuvant action of a detoxified endotoxin","volume":"8","author":"Tomai","year":"1989","journal-title":"J Biol Resp Modifiers"},{"key":"10.1016\/j.vaccine.2007.01.111_bib50","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/med.2610060302","article-title":"Natural and synthetic trehalose diesters as immunomodulators","volume":"6","author":"Lemaire","year":"1986","journal-title":"Med Res Rev"},{"key":"10.1016\/j.vaccine.2007.01.111_bib51","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1073\/pnas.94.20.10833","article-title":"Immunostimulatory oligodeoxynucletides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization","volume":"94","author":"Weiner","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2007.01.111_bib52","first-page":"477","article-title":"Studies for safety of adjuvant 65","volume":"30","author":"Hilleman","year":"1972","journal-title":"Ann Allergy"},{"key":"10.1016\/j.vaccine.2007.01.111_bib53","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1017\/S0022172400024323","article-title":"Response to influenza vaccine in adjuvant 65-4","volume":"74","author":"Smith","year":"1975","journal-title":"J Hyg (Camb)"},{"key":"10.1016\/j.vaccine.2007.01.111_bib54","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3181\/00379727-143-37469","article-title":"Ten-year follow-up study for safety of Adjuvant 65 influenza vaccine in man","volume":"143","author":"Weibel","year":"1973","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2007.01.111_bib55","first-page":"50","article-title":"The mode of action immunological adjuvants","volume":"7","author":"Freund","year":"1956","journal-title":"Adv Tuberc Res"},{"key":"10.1016\/j.vaccine.2007.01.111_bib56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0264-410X(85)90063-5","article-title":"Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants","volume":"3","author":"Woodard","year":"1985","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib57","first-page":"149","article-title":"Studies on the adjuvant effect of water-in-oil-in-water emulsion in sesame oil. I. Enhanced and persistent antibody formation by antigen incorporated into the water-in-oil-in-water emulsion","volume":"48","author":"Kimura","year":"1978","journal-title":"Jpn J Exp Med"},{"key":"10.1016\/j.vaccine.2007.01.111_bib58","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1017\/S0022172400063117","article-title":"Antibody responses and resistance to challenge in volunteers vaccinated with live attenuaded detergent split and oil adjuvant A2\/Hong Kong\/68 (H3N2) influenza vaccines","volume":"70","author":"Freestone","year":"1972","journal-title":"J Hyg (Camb)"},{"key":"10.1016\/j.vaccine.2007.01.111_bib59","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1017\/S0022172400041905","article-title":"Antibody response and reactions to aqueous influenza vaccine, simple emulsion vaccine and multiple emulsion vaccine","volume":"67","author":"Taylor","year":"1969","journal-title":"J Hyg (Camb)"},{"key":"10.1016\/j.vaccine.2007.01.111_bib60","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0165-2478(90)90008-E","article-title":"Peptide vaccine derived from a malarial surface antigen: effect of dose and adjuvant on immunogenicity","volume":"24","author":"Jones","year":"1990","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2007.01.111_bib61","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.addr.2004.09.008","article-title":"Immunity in response to particulate antigen-delivery systems","volume":"57","author":"Storni","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2007.01.111_bib62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v22.i2.20","article-title":"Particulate delivery systems for vaccines","volume":"22","author":"Bramwell","year":"2005","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.vaccine.2007.01.111_bib63","first-page":"37","article-title":"Comparison between multilamellar and unilamellar liposomes in enhancing antibody formation","volume":"49","author":"Shek","year":"1983","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2007.01.111_bib64","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/252252a0","article-title":"Liposomes as immunological adjuvants","volume":"252","author":"Allison","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2007.01.111_bib65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1042\/bst0040129","article-title":"The adjuvant properties of liposomes","volume":"4","author":"Heath","year":"1976","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.vaccine.2007.01.111_bib66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0304-4157(76)90002-2","article-title":"New aspects of liposomes","volume":"457","author":"Tyrrel","year":"1976","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.vaccine.2007.01.111_bib67","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0076-6879(83)93036-7","article-title":"Use of liposomes as biodegradable and harmless adjuvants","volume":"93","author":"van Rooijen","year":"1983","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib68","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.4049\/jimmunol.177.4.2324","article-title":"Antigen chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity","volume":"177","author":"Taneichi","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib69","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/08982100600880432","article-title":"The \u2019co-delivery\u2019 approach to liposomal vaccines: application to the development of influenza-A and hepatitis-B vaccine candidates","volume":"16","author":"Laing","year":"2006","journal-title":"J Liposome Res"},{"key":"10.1016\/j.vaccine.2007.01.111_bib70","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0161-5890(91)90076-V","article-title":"Biodegradable microspheres as a vaccine delivery system","volume":"28","author":"Eldrige","year":"1991","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib71","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/IAI.59.9.2978-2986.1991","article-title":"Biodegradable and biocompatible poly (dl-lactide-co-glycolide) microspheres as an adjuvant for Staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies","volume":"59","author":"Eldrige","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2007.01.111_bib72","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/156720106775197565","article-title":"Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems","volume":"3","author":"Singh","year":"2006","journal-title":"Curr Drug Deliv"},{"key":"10.1016\/j.vaccine.2007.01.111_bib73","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nm0795-649","article-title":"Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity","volume":"1","author":"Falo","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2007.01.111_bib74","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.4049\/jimmunol.173.5.3148","article-title":"Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors","volume":"173","author":"Fifis","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib75","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.vaccine.2005.09.009","article-title":"Systemic immune responses in sheep, induced by a novel nano-bead adjuvant","volume":"24","author":"Scheerlinck","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib76","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1051\/vetres:2006014","article-title":"Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa","volume":"37","author":"Cox","year":"2006","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2007.01.111_bib77","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.addr.2004.09.006","article-title":"ISCOMATRIX adjuvant for antigen delivery","volume":"57","author":"Pearse","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2007.01.111_bib78","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1586\/14760584.5.3.395","article-title":"Achieving directed immunostimulating complexes incorporation","volume":"5","author":"Wikman","year":"2006","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2007.01.111_bib79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymeth.2006.05.019","article-title":"Saponin-adjuvanted particulate vaccines for clinical use","volume":"40","author":"Skene","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2007.01.111_bib80","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1016\/j.vaccine.2006.03.089","article-title":"A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure","volume":"24","author":"Antonis","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib81","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1016\/j.vaccine.2006.03.052","article-title":"Transcutaneous vaccination with virus-like particles","volume":"24","author":"Young","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib82","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.vaccine.2005.11.060","article-title":"Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels","volume":"24","author":"Dell","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib83","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2006.01.040","article-title":"Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults","volume":"117","author":"Kundig","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib84","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.0818-9641.2004.01278.x","article-title":"Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen","volume":"82","author":"Aguilar","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib85","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.molimm.2004.09.005","article-title":"Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen","volume":"42","author":"Lobaina","year":"2005","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib86","doi-asserted-by":"crossref","unstructured":"Aguilar A, Gonz\u00e1lez C, Cinza Z, Mart\u00ednez J, V\u00e9liz G, Aureoles-Rosell\u00f3 SR, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant Hepatitis B surface and core antigens. Int J Infect Dis, 2007, doi:10.1016\/j.ijid.2006.09.010.","DOI":"10.1016\/j.ijid.2006.09.010"},{"key":"10.1016\/j.vaccine.2007.01.111_bib87","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1084\/jem.167.2.700","article-title":"Granulocyte\/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells","volume":"167","author":"Heufler","year":"1988","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2007.01.111_bib88","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1529-1049(02)00051-X","article-title":"The use of cytokines and chemokines as genetic adjuvants for plasmid DNA vaccines","volume":"2","author":"Egan","year":"2002","journal-title":"Clin Appl Immunol Rev"},{"key":"10.1016\/j.vaccine.2007.01.111_bib89","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1128\/IAI.71.8.4780-4788.2003","article-title":"Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12","volume":"71","author":"Lynch","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2007.01.111_bib90","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1128\/JVI.76.2.517-524.2002","article-title":"Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization","volume":"76","author":"Bradney","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib91","series-title":"Vaccine design: the subunit and adjuvant approach","first-page":"559","article-title":"Vaccine adjuvants based on gamma inulin","author":"Cooper","year":"1995"},{"key":"10.1016\/j.vaccine.2007.01.111_bib92","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0264-410X(91)90063-C","article-title":"Algammulin: a new vaccine adjuvant comprising gamma inulin particles containing alum, preparation and in vitro properties","volume":"9","author":"Cooper","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib93","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/0264-410X(91)90127-R","article-title":"The adjuvanticity of algammulin, a new vaccine adjuvant","volume":"9","author":"Cooper","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib94","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1440-1711.2004.01290.x","article-title":"Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses","volume":"82","author":"Silva","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib95","first-page":"955","article-title":"Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity","volume":"72","author":"Tokunaga","year":"1984","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2007.01.111_bib96","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib97","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.4049\/jimmunol.171.3.1393","article-title":"Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation","volume":"171","author":"Gursel","year":"2003","journal-title":"J Immunol"},{"issue":"21","key":"10.1016\/j.vaccine.2007.01.111_bib98","doi-asserted-by":"crossref","first-page":"12631","DOI":"10.1073\/pnas.95.21.12631","article-title":"Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs","volume":"95","author":"Krieg","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2007.01.111_bib99","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.0300-9475.2004.01373.x","article-title":"Methylated CpG-containing plasmid activates the immune system","volume":"59","author":"Cornelie","year":"2004","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib100","doi-asserted-by":"crossref","first-page":"15124","DOI":"10.1074\/jbc.M313406200","article-title":"Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition","volume":"279","author":"Cornelie","year":"2004","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.vaccine.2007.01.111_bib101","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nri1329","article-title":"Immunotherapeutic uses of CpG oligodeoxynucleotides","volume":"4","author":"Klinman","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib102","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/dna.2005.24.63","article-title":"Superior activity of the type C class of ISS in vitro and in vivo across multiple species","volume":"24","author":"Marshall","year":"2005","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib103","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1096\/fj.03-0646fje","article-title":"Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice","volume":"18","author":"Anders","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.vaccine.2007.01.111_bib104","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1191\/0961203305lu2102rr","article-title":"A toll for lupus","volume":"14","author":"Anders","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.vaccine.2007.01.111_bib105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.0105-2896.2004.00149.x","article-title":"Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications","volume":"199","author":"Datta","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2007.01.111_bib106","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0006-291X(03)01462-1","article-title":"Duarte CA Enhanced cell-mediated IFN-g-secreting activity against the HIV-1IIIB V3 peptide of the TAB9 multiepitope after DNA vaccine backbone engineering","volume":"308","author":"Rodr\u00edguez","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2007.01.111_bib107","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nri776","article-title":"New hope for an AIDS vaccine","volume":"2","author":"Robinson","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib108","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1111\/j.1523-1755.2005.00689.x","article-title":"Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients","volume":"68","author":"Tong","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.vaccine.2007.01.111_bib109","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib110","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2007.01.111_bib111","doi-asserted-by":"crossref","first-page":"S2-26","DOI":"10.1016\/j.vaccine.2005.01.107","article-title":"Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity","volume":"24","author":"Petrovsky","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib112","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/978-1-4615-1823-5_24","article-title":"Vaccine adjuvants based on gamma inulin","volume":"6","author":"Cooper","year":"1995","journal-title":"Pharm Biotechnol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib113","doi-asserted-by":"crossref","first-page":"S2-90","DOI":"10.1016\/j.vaccine.2005.01.137","article-title":"Liposomal preparations of muramyl glycopeptides as immunomodulators and adjuvants","volume":"24","author":"Turanek","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib114","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejpb.2006.05.005","article-title":"Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN","volume":"64","author":"Tafaghodi","year":"2006","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2007.01.111_bib115","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/intimm\/dxh186","article-title":"Toll-like receptors in innate immunity","volume":"17","author":"Takeda","year":"2005","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib117","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1128\/IAI.73.3.1343-1349.2005","article-title":"Toll-like receptor 2 mediates cellular activation by the B subunits of type II heat-labile enterotoxins","volume":"73","author":"Hajishengallis","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2007.01.111_bib118","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.4049\/jimmunol.173.4.2683","article-title":"Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses","volume":"173","author":"Schroder","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib119","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.4049\/jimmunol.174.11.7096","article-title":"Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2\/TLR4 activation","volume":"174","author":"Uehori","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib120","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.intimp.2004.04.012","article-title":"Triacyl-lipopentapeptide adjuvants: TLR2-dependent activation of macrophages and modulation of receptor-mediated cell activation by altering acyl-moieties","volume":"4","author":"Muller","year":"2004","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib121","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.cji.0000156828.75196.0d","article-title":"Defining the antigen-specific T-cell response to vaccination and poly(I:C)\/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity","volume":"28","author":"Salem","year":"2005","journal-title":"J Immunother"},{"key":"10.1016\/j.vaccine.2007.01.111_bib122","doi-asserted-by":"crossref","first-page":"9943","DOI":"10.1128\/JVI.01036-06","article-title":"Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production","volume":"80","author":"Gill","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib123","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1517\/14712598.4.7.1129","article-title":"Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents","volume":"4","author":"Baldridge","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2007.01.111_bib124","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.vaccine.2006.08.013","article-title":"Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity","volume":"25","author":"Huleatt","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib125","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/intimm\/13.7.933","article-title":"Discrimination of bacterial lipoproteins by Toll-like receptor 6","volume":"13","author":"Takeuchi","year":"2001","journal-title":"Int Immunol"},{"issue":"Suppl 66","key":"10.1016\/j.vaccine.2007.01.111_bib126","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.0366-077X.2003.05626.x","article-title":"The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview","volume":"149","author":"Stockfleth","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib127","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1016\/j.vaccine.2005.06.024","article-title":"TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)","volume":"23","author":"Weeratna","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.111_bib128","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2007.01.111_bib129","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.4049\/jimmunol.168.10.4951","article-title":"Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain","volume":"168","author":"Riedl","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2007.01.111_bib130","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1440-1711.2005.01408.x","article-title":"Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV-1","volume":"84","author":"Iglesias","year":"2006","journal-title":"Immunol Cell Biol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07001703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07001703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T21:37:23Z","timestamp":1736804243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07001703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":130,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0264410X07001703"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.01.111","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}